244 related articles for article (PubMed ID: 26719532)
1. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic Therapy Using Photosensitizer-Encapsulated Polymeric Nanoparticle to Overcome ATP-Binding Cassette Transporter Subfamily G2 Function in Pancreatic Cancer.
Roh YJ; Kim JH; Kim IW; Na K; Park JM; Choi MG
Mol Cancer Ther; 2017 Aug; 16(8):1487-1496. PubMed ID: 28416605
[TBL] [Abstract][Full Text] [Related]
3. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model.
Sostelly A; Payen L; Guitton J; Di Pietro A; Falson P; Honorat M; Boumendjel A; Gèze A; Freyer G; Tod M
Fundam Clin Pharmacol; 2014 Apr; 28(2):161-9. PubMed ID: 23384250
[TBL] [Abstract][Full Text] [Related]
5. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan (Campto) in the treatment of pancreatic cancer.
Pizzolato JF; Saltz LB
Expert Rev Anticancer Ther; 2003 Oct; 3(5):587-93. PubMed ID: 14599083
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Ko AH
Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.
Liu W; Baer MR; Bowman MJ; Pera P; Zheng X; Morgan J; Pandey RA; Oseroff AR
Clin Cancer Res; 2007 Apr; 13(8):2463-70. PubMed ID: 17438106
[TBL] [Abstract][Full Text] [Related]
9. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
Shishido Y; Ueno S; Yamazaki R; Nagaoka M; Matsuzaki T
Anticancer Res; 2013 Apr; 33(4):1379-86. PubMed ID: 23564776
[TBL] [Abstract][Full Text] [Related]
10. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
[TBL] [Abstract][Full Text] [Related]
11. Critical role of ABCG2 in ALA-photodynamic diagnosis and therapy of human brain tumor.
Ishikawa T; Kajimoto Y; Inoue Y; Ikegami Y; Kuroiwa T
Adv Cancer Res; 2015; 125():197-216. PubMed ID: 25640271
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
Canu B; Fioravanti A; Orlandi P; Di Desidero T; Alì G; Fontanini G; Di Paolo A; Del Tacca M; Danesi R; Bocci G
Neoplasia; 2011 Mar; 13(3):217-29. PubMed ID: 21390185
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
Noble CO; Krauze MT; Drummond DC; Forsayeth J; Hayes ME; Beyer J; Hadaczek P; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
Nanomedicine (Lond); 2014 Jul; 9(14):2099-108. PubMed ID: 24494810
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
[TBL] [Abstract][Full Text] [Related]
15. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles.
Peng CL; Lai PS; Lin FH; Yueh-Hsiu Wu S; Shieh MJ
Biomaterials; 2009 Jul; 30(21):3614-25. PubMed ID: 19395020
[TBL] [Abstract][Full Text] [Related]
16. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Arnaud O; Boumendjel A; Gèze A; Honorat M; Matera EL; Guitton J; Stein WD; Bates SE; Falson P; Dumontet C; Di Pietro A; Payen L
Eur J Cancer; 2011 Mar; 47(4):640-8. PubMed ID: 21216589
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.
Liu X; Situ A; Kang Y; Villabroza KR; Liao Y; Chang CH; Donahue T; Nel AE; Meng H
ACS Nano; 2016 Feb; 10(2):2702-15. PubMed ID: 26835979
[TBL] [Abstract][Full Text] [Related]
18. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers.
Kim JH; Park JM; Roh YJ; Kim IW; Hasan T; Choi MG
BMC Cancer; 2015 Jul; 15():504. PubMed ID: 26149077
[TBL] [Abstract][Full Text] [Related]
20. Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer.
Bien H; Mackenzie GG; Choi M
Recent Pat Anticancer Drug Discov; 2016; 11(4):376-383. PubMed ID: 27480831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
